The FDA has lowered the age limit for Plan B One-Step emergency contraceptive to 15. The pill will be available without a prescription and stocked on store shelves.
One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.
Pfizer will report earnings on Tuesday before the market open. The FMHR traders debate the bull and the bear case for the stock. Barbara Ryan, FTI Strategic Communications, shares her recommendations for investing in pharma stocks now.
Novartis plied physicians with dinners, speaker fees, fishing trips and outings at Hooters restaurants to get them to prescribe patients more Novartis drugs, the US government alleges. Globalpost reports.
Germany's Bayer has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider.
A proposed merger of Valeant Pharmaceuticals International Inc and Actavis Inc. was put on hold after the two drugmakers failed to agree on terms of a deal.
Get ready. Cramer sees the potential for problems around Wednesday.
Michael Sinclair, CEO of Advanced Oncotherapy, explains why his company acquired Swiss firm Adam SA this week, citing its leadership in technology advancements.
Pockets of weakness in the market have captured Cramer's attention. Is the selling really warranted?
Novartis was sued on Tuesday by the United States, which accused the Swiss drug maker of using kickbacks to induce pharmacies to steer thousands of patients to its drug.
Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.
Big pharma is abandoning antibiotic research at a time when fears over superbugs are growing at an alarming rate, leaving smaller firms to fill the breach.
It will take a mix of approaches to make health care more affordable, Johnson & Johnson CEO Alex Gorsky told CNBC.
Antibiotic-resistant bacteria—often called "superbugs"—are entering the nation's food system and endangering consumers at an alarming rate, according to an analysis of government data.
A British professor says that drug abuse helped bring about the financial crisis, but he may have pinned the blame on the wrong drug.
Stocks bounced back on Tuesday. But what should you make of the leadership?
Some cancers could be cured within the next couple of years, Celgene CEO Robert Hugin told CNBC.
Eli Lilly plans to slash 1,000 sales jobs in a "major restructuring," a source familiar with the plans said.
China is handling an outbreak of bird flu much better than in the past, Sanofi CEO Chris Viehbacher told CNBC on Thursday.
Markets can expect a wave of new medicines over the next few years, said John Lechleiter, Eli Lilly's president and CEO.